Results 91 to 100 of about 69,036 (281)
Somatic cell reprogramming for Parkinson's disease treatment
Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley +1 more source
Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson's Disease. [PDF]
, 2019 ObjectiveIn Parkinson's disease (PD), vitamin B12 levels are lower, and comorbid B12 deficiency has been associated with the development of neuropathy and early gait instability.
Christine, Chadwick W +3 more
core
Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. [PDF]
, 2013 A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a ...
Arulselvan, Palanisamy +4 more
core +2 more sources
iNew Medicine, EarlyView.In the freezing of gait in Parkinson's disease, white matter shows decreased local activity but increased functional connectivity. These distinct dysfunctions are uniquely associated with specific neurotransmitter systems (GABA, dopamine, etc.), mapping a new neurochemical basis for this debilitating symptom. ABSTRACT Freezing of gait (FOG) is a severe
Pingping Liu +10 more
wiley +1 more source
Long-term Effects of Cabergoline and Levodopa in Japanese Patients with Early Parkinson’s Disease: A 5-Year Prospective Study [PDF]
, 2012 Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications.
Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group, +1 more
core +1 more source
Indirubin and Retinoic Acid Show Binding Affinity to Monocyte Biomarker CSF3R in Parkinson's Disease
Journal of Clinical Laboratory Analysis, EarlyView.Through single‐cell RNA‐sequencing and high‐dimensional weighted gene co‐expression network analysis, two monocyte‐related biomarkers (CSF3R, IFITM3) were identified in the peripheral blood of Parkinson's disease. Molecular docking revealed two targeted drugs (Indirubin and Retinoic acid).
Zhiwei Bao, Shao Zhi, Mao Jie
wiley +1 more source
Frontiers in Neurology, 2019 Parkinson's disease is the second-most common neurodegenerative disorder worldwide. Besides deciphering the mechanisms that underlie the etiology of the disease, it is important to elucidate the factors that influence the efficacy of the treatment ...
Sebastiaan P. van Kessel, Sahar El Aidy
doaj +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Apathy is a common early symptom of Parkinson's disease (PD), often co‐occurring with cognitive decline and associated with fronto‐striatal and mesocortico‐limbic dysfunctions. Discrepancies between self‐ and caregiver‐reported apathy have been preliminarily associated with cognitive impairments affecting patients’ awareness and ...
Giulia Funghi +13 more
wiley +1 more source
Investigating Sleep Concerns in Cervical Dystonia
Movement Disorders Clinical Practice, EarlyView.Abstract Background Heterogenous, small cohorts, and co‐occurrence of pain and psychiatric burden complicate understanding of sleep in dystonia. Objective To investigate sleep concerns in cervical dystonia (CD). Methods Longitudinal data from CD‐PROBE on subjects who were toxin‐naïve, new to practice, or without injections for at least 16 weeks were ...
Abhimanyu Mahajan +2 more
wiley +1 more source
Sleep disturbance and serum ferritin levels associate with high impulsivity and impulse control disorders in male Parkinson\u27s Disease patients [PDF]
, 2017 Impulse control disorders (ICDs) occur in a subset of Parkinson’s disease (PD) patients on dopaminergic medications however there are currently no reliable markers to identify patients at risk.
Anderton, R +6 more
core +1 more source